News | Breast Imaging | July 26, 2022

The category-defining Imagio Breast Imaging System helps physicians differentiate between benign and malignant breast lesions using a novel combination of ultrasound and opto-acoustic technology 

The Imagio Breast Imaging System helps physicians differentiate between benign and malignant breast lesions using non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information on breast lesions in real time, helping providers to characterize and differentiate masses that may — or may not — require more invasive diagnostic evaluation.

The Imagio Breast Imaging System helps physicians differentiate between benign and malignant breast lesions using non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information on breast lesions in real time, helping providers to characterize and differentiate masses that may — or may not — require more invasive diagnostic evaluation. 


July 26, 2022 — Seno Medical’s Imagio Breast Imaging System, a revolutionary new modality in breast imaging, has received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA). Seno’s market-ready, groundbreaking diagnostic breast cancer imaging system helps physicians differentiate between benign and malignant breast lesions using non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information on breast lesions in real time, helping providers to characterize and differentiate masses that may — or may not — require more invasive diagnostic evaluation. 

The Imagio Breast Imaging System incorporates state-of-the-art ultrasound imaging technology required for premier breast imaging centers, as well as advanced ultrasound technology integrated into the opto-acoustic probe, a new ultrasound probe, and elimination of redundant electronics, making this version of Imagio more ergonomic and truly disruptive for the marketplace with the latest technological advances. 

Tom Umbel, President and CEO of Seno Medical, commented, “This team is passionately committed to providing a revolutionary leap forward in patient care, and our commercial version of our Imagio System delivers just that. With our novel OA/US platform, combined with the latest technologies available today in breast imaging, we are delivering a new hybrid modality that will help providers deliver the best care possible to their patients.” 

The company is launching a mobile education and demonstration tour, Imagio OA/US Road Show - Scans Across America, to enable on-site, hands-on demonstration with the Imagio System throughout the United States. The Imagio OA/US Road Show - Scans Across America tour will begin in late July with continued stops across the countbreastry throughout 2022. 

Breast biopsy procedures, caused by false-positive diagnostic assessments, cost the US healthcare system more than $2 billion per year.[i] Seno’s Imagio technology could significantly reduce those costs with its non-invasive OA/US innovation. 

Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging. The opto-acoustic images provide a unique blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer — angiogenesis and hypoxia — Seno Medical has shown that the Imagio OA/US Breast Imaging System will be a more effective tool to help radiologists confirm or rule out malignancy compared with traditional diagnostic imaging modalities. And it does this without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. In addition to the novel imaging provided by the Imagio System, Seno includes an artificial intelligence (AI) decision-support tool (SenoGram) to aid physicians in interpreting the new images. This AI tool, along with training and certification, helps radiologists transition from ultrasound alone to OA/US imaging. 

The system is indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up following clinical presentation or other imaging examinations such as screening mammography

For more information: www.SenoMedical.com 

Reference: [i] Vlahiotis A, Griffin B, Stavros AT, Margolis J. Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography. Clinicoeconomics Outcomes Res 2018;10:157-167. 


Related Content

News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Breast Imaging

February 9, 2024 — An innovative breast imaging technique provides high sensitivity for detecting cancer while ...

Time February 09, 2024
arrow
News | Radiology Business

February 1, 2024 — Theragenics Corporation, a global leader in minimally invasive brachytherapy, interventional devices ...

Time February 01, 2024
arrow
News | FDA

January 30, 2024 — IceCure Medical Ltd. has announced the U.S. Food and Drug Administration (FDA) has responded ...

Time January 30, 2024
arrow
News | Breast Imaging

January 29, 2024 — Diagnoses of breast cancer have increased steadily in women under age 50 over the past two decades ...

Time January 29, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time January 29, 2024
arrow
News | Artificial Intelligence

January 22, 2024 — b-rayZ, a Swiss innovator in AI-powered medical imaging solutions, proudly announces the receipt of ...

Time January 22, 2024
arrow
Subscribe Now